34th International Congress of the ISBT

Cerus will be present at the 34th International Congress of the International Society of Blood Transfusion (ISBT), taking place at the Dubai World Trade Centre, Dubai, United Arab Emirates, from 3 to 8 September.

The ISBT is an international society of transfusion medicine professionals from across the globe, who come together to share knowledge to improve the safety of blood transfusion worldwide.

On Tuesday, September 6th from 12:00 to 13:30 a Cerus Symposium “Pathogen Inactivation: Towards a global standard of care for transfused blood components” will take place in the Sheikh Maktoum D room.


The symposium presenters will offer compelling first-hand accounts of three topics: pathogen inactivation and AABB accreditation; managing a Zika outbreak; and the affordability of pathogen inactivation for platelet concentrates. Here are details on the symposium speakers and topics:


Pathogen Inactivation for Platelets and Plasma Under AABB Accreditation

Dr. Reem Al Radwan, Kuwait Central Blood Bank

Operating within the stringent guidelines required for AABB accreditation for the past five years, the Kuwait Central Blood Bank depends on the INTERCEPT™ Blood System for pathogen inactivation of platelets and plasma. Dr. Reem Al Radwan will talk about how pathogen inactivation aligns with the internationally-recognized AABB standards.

Managing a ZIKA Outbreak in French Polynesia

Dr. Didier Musso, Institut Louis Malarde, Papeete, Tahiti

Where Zika is present, INTERCEPT should be present too. Drawing on his first-hand experience and research, Dr. Didier Musso will talk about the value of the INTERCEPT Blood System and pathogen inactivation in regard to the Zika virus outbreak in French Polynesia.

Affordable Production of Pathogen-Inactivated Platelet Concentrates

Hanna-Stina Ahlzén & Linda Larsson, Karolinska University Hospital, Sweden

This presentation will explore pathogen inactivation from a budget point-of-view, examining the technical and economic implications of implementing PI technology, and how blood banks and hospitals can recoup an investment in PI in operations.


INTERCEPT, the world’s leading pathogen inactivation technology, will also be discussed in two oral presentations that will be delivered at ISBT Dubai:

Effective Inactivation of the Non-Enveloped Feline Calicivirus With Amustaline/GSH In Red Blood Cells

Felicia Santa Maria, Andrew Laughhunn, Raymond Lenhoff - Microbiology Department, CerusCorporation, Concord, CA

Adonis Stassinopoulos - Global Scientific Affairs Cerus Corporation, Concord, CA

Validation of a Novel Double Dose Buffy Coat Platelet Pooling Set In Combination With Photochemical Treatment

Per Sandgren, Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden

Inactivation of Chikungunya Virus With Amustaline/GSH In Red Blood Cells

Andrew Laughhunn, Cerus Corporation, Microbiology Department, US

Yan-Jang S. Huang, Dana Vanlandingham, Biosecurity Research Institute , Kansas State University, US Adonis Stassinopoulos, Cerus Corporation, Global Scientific Affairs, US


In addition, pathogen inactivation and INTERCEPT will be included in 12 poster presentations at the congress.


Visit us at out booth number 7309. 

Visit the ISBT website